NCT02495519View on ClinicalTrials.gov

A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Fibromatosis
Interventions
DRUG

Imatinib

Imatinib 400 mg/day until disease progression

Trial Locations (1)

120-752

Severance Hospital, Yonsei University Health System, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02495519 - A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis) | Biotech Hunter | Biotech Hunter